Search
Dienestrol
go.drugbank.com/drugs/DB00890ApprovedWithdrawnEstrogens work partly by increasing a normal clear discharge from the vagina and making the vulva and urethra healthy. … Dienestrol is a synthetic, non-steroidal estrogen. It is an estrogen receptor agonist.
Categories: Estrogens, Non-SteroidalValrubicin
go.drugbank.com/drugs/DB00385ApprovedUsed in the treatment of the bladder cancer, valrubicin is administered by direct infusion into the bladder. … Valrubicin (N-trifluoroacetyladriamycin-14-valerate) is a chemotherapy drug commonly marketed under the trade name VALSTAR.
Trifluridine
go.drugbank.com/drugs/DB00432ApprovedInvestigationalTrifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine] [A35271]. … It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus.
Dexbrompheniramine
go.drugbank.com/drugs/DB00405ApprovedDexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria.
Synonyms: 3-(4-bromophenyl)- N,N-dimethyl- 3-pyridin-2-yl-propan-1-amineMixtures: Dologesic NF, WesTussin DM NFBinimetinib
go.drugbank.com/drugs/DB11967ApprovedInvestigationalwith unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test. … [A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients
Botulinum toxin type B
go.drugbank.com/drugs/DB00042ApprovedNeurotoxin produced by fermentation of clostridium botulinum type B. The protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin complex.
Parachlorophenol
go.drugbank.com/drugs/DB13154ApprovedWithdrawnSlightly soluble to soluble in water, depending on the isomer, and denser than water. Noncombustible.
Prademagene zamikeracel
go.drugbank.com/drugs/DB17895ApprovedInvestigational[L53008] Prademagene zamikeracel was first approved by the FDA on April 29, 2025, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a skin disorder associated with excessive blistering … [L53013] It was granted an Orphan Drug designation by the EMA.[A273833]
Macimorelin
go.drugbank.com/drugs/DB13074ApprovedMacimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution. … In addition, individuals with may be susceptible to cardiovascular complications from altered structures and function [A31484].
Phenacemide
go.drugbank.com/drugs/DB01121ApprovedPhenacemide is used to control certain seizures in the treatment of epilepsy. This medicine acts on the central nervous system (CNS) to reduce the number and severity of seizures.